The Role of CARD9 in Metabolic Diseases

Abstract

Caspase recruitment domain containing protein 9 (CARD9) is an adaptor protein that plays a critical role in pattern recognition receptors (PRRs)-mediated activation of NF-?B and mitogen-activated protein kinase (MAPK). This elicits initiation of the pro-inflammatory cytokines and leads to inflammatory responses, which has been recognized as a critical contributor to chronic inflammation. Current researches demonstrate that CARD9 is strongly associated with metabolic diseases, such as obesity, insulin resistance, atherosclerosis and so on. In this review, we summarize CARD9 signaling pathway and the role of CARD9 in metabolic diseases.

Keywords

caspase recruitment domain containing protein 9 / pattern recognition receptors / metabolic diseases

References

[1] GakidouE, AfshinA, AbajobirAA, et al.. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 2017, 390(10100): 1345-1422

[2] BakerRG, HaydenMS, GhoshS. NF-kappaB, inflammation, and metabolic disease. Cell Metab, 2011, 13(1): 11-22

[3] LuoP, YangZ, ChenB, et al.. The multifaceted role of CARD9 in inflammatory bowel disease. J Cell Mol Med, 2020, 24(1): 34-39

[4] RothS, RulandJ. Caspase recruitment domain-containing protein 9 signaling in innate immunity and inflammation. Trends Immunol, 2013, 34(6): 243-250

[5] ZengX, DuX, ZhangJ, et al.. The essential function of CARD9 in diet-induced inflammation and metabolic disorders in mice. J Cell Mol Med, 2018, 22(6): 2993-3004

[6] CaoL, QinX, PetersonMR, et al.. CARD9 knockout ameliorates myocardial dysfunction associated with high fat diet-induced obesity. J Mol Cell Cardiol, 2016, 92: 185-195

[7] BertinJ, GuoY, WangL, et al.. CARD9 is a novel caspase recruitment domain-containing protein that interacts with BCL10/CLAP and activates NF-kappa B. J Biol Chem, 2000, 275(52): 41 082-41 086

[8] ZhongX, ChenB, YangL, et al.. Molecular and physiological roles of the adaptor protein CARD9 in immunity. Cell Death Dis, 2018, 9(2): 52

[9] VaeziA, FakhimH, AbtahianZ, et al.. Frequency and Geographic Distribution of CARD9 Mutations in Patients With Severe Fungal Infections. Front Microbiol, 2018, 9: 2434-2440

[10] GrossO, GewiesA, FingerK, et al.. Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature, 2006, 442(7103): 651-656

[11] AtifSM, LeeSJ, LiLX, et al.. Rapid CD4+ T-cell responses to bacterial flagellin require dendritic cell expression of Syk and CARD9. Eur J Immunol, 2015, 45(2): 513-524

[12] MaJ, AbramCL. CARD9 mediates dendritic cell-induced development of Lyn deficiency-associated autoimmune and inflammatory diseases. Front Microbiol, 2019, 12(602): eaao3829

[13] HsuYM, ZhangY, YouY, et al.. The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens. Nat Immunol, 2007, 8(2): 198-205

[14] PoeckH, BscheiderM, GrossO, et al.. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nat Immunol, 2010, 11(1): 63-69

[15] DrummondRA, SaijoS, IwakuraY, et al.. The role of Syk/CARD9 coupled C-type lectins in antifungal immunity. Eur J Immunol, 2011, 41(2): 276-281

[16] StrasserD, NeumannK, BergmannH, et al.. Syk kinase-coupled C-type lectin receptors engage protein kinase C-sigma to elicit Card9 adaptor-mediated innate immunity. Immunity, 2012, 36(1): 32-42

[17] JiaXM, TangB, ZhuLL, et al.. CARD9 mediates Dectin-1-induced ERK activation by linking Ras- GRF1 to H-Ras for antifungal immunity. J Exp Med, 2014, 211(11): 2307-2321

[18] WagenerM, HovingJC, NdlovuH, et al.. Dectin-1- Syk-CARD9 Signaling Pathway in TB Immunity. Front Immunol, 2018, 9: 225-231

[19] RothS, BergmannH, JaegerM, et al.. Vav Proteins Are Key Regulators of Card9 Signaling for Innate Antifungal Immunity. Cell Rep, 2016, 17(10): 2572-2583

[20] CaoZ, ConwayKL, HeathRJ, et al.. The Ubiquitin Ligase TRIM62 Regulates CARD9-Mediated Anti-fungal Immunity and Intestinal Inflammation. Immunity, 2015, 43(4): 715-726

[21] YangCS, RodgersM, MinCK, et al.. The autophagy regulator Rubicon is a feedback inhibitor of CARD9- mediated host innate immunity. Cell Host Microbe, 2012, 11(3): 277-289

[22] YangH, MinamishimaYA, YanQ, et al.. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell, 2007, 28(1): 15-27

[23] HaraH, IshiharaC, TakeuchiA, et al.. The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors. Nat Immunol, 2007, 8(6): 619-629

[24] LooYM, GaleMJr. Immune signaling by RIG-I-like receptors. Immunity, 2011, 34(5): 680-692

[25] RothS, RottachA, Lotz-HavlaAS, et al.. Rad50- CARD9 interactions link cytosolic DNA sensing to IL- 1beta production. Nat Immunol, 2014, 15(6): 538-545

[26] RathinamVA, JiangZ, WaggonerSN, et al.. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol, 2010, 11(5): 395-402

[27] SellH, HabichC, EckelJ. Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol, 2012, 8(12): 709-716

[28] McLaughlinT, AckermanSE, ShenL, et al.. Role of innate and adaptive immunity in obesity-associated metabolic disease. J Clin Invest, 2017, 127(1): 5-13

[29] FriasJP, YuJG, KruszynskaYT, et al.. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects. Diabetes Care, 2000, 23(1): 64-69

[30] KockG, BringmannA, HeldSA, et al.. Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone. Blood, 2011, 117(13): 3569-3574

[31] CastoldiA, Andrade-OliveiraV, AguiarCF, et al.. Dectin-1 Activation Exacerbates Obesity and Insulin Resistance in the Absence of MyD88. Cell Rep, 2017, 19(11): 2272-2288

[32] VorugantiVS, LastonS, HaackK, et al.. Genome-wide association replicates the association of Duffy antigen receptor for chemokines (DARC) polymorphisms with serum monocyte chemoattractant protein-1 (MCP-1) levels in Hispanic children. Cytokine, 2012, 60(3): 634-638

[33] WangS, GuJ, XuZ, et al.. Zinc rescues obesity-induced cardiac hypertrophy via stimulating metallothionein to suppress oxidative stress-activated BCL10/CARD9/ p38 MAPK pathway. J Cell Mol Med, 2017, 21(6): 1182-1192

[34] BiobakuF, GhanimH, BatraM, et al.. Macronutrient- Mediated Inflammation and Oxidative Stress: Relevance to Insulin Resistance, Obesity, and Atherogenesis. J Clin Endocrinol Metab, 2019, 104(12): 6118-6128

[35] LackeyDE, OlefskyJM. Regulation of metabolism by the innate immune system. Nat Rev Endocrinol, 2016, 12(1): 15-28

[36] HotamisligilGS, ShargillNS, SpiegelmanBM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 1993, 259(5091): 87-91

[37] PandoriWJ, LimaTS. Toxoplasma gondii activates a Syk-CARD9-NF-kappaB signaling axis and gasdermin D-independent release of IL-1beta during infection of primary human monocytes. PLoS Pathog, 2019, 15(8): e1007923

[38] YangZW, MengXX, ZhangC, et al.. CARD9 gene silencing with siRNA protects rats against severe acute pancreatitis: CARD9-dependent NF-kappaB and P38MAPKs pathway. J Cell Mol Med, 2017, 21(6): 1085-1093

[39] BertolaA, CiucciT, RousseauD, et al.. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes, 2012, 61(9): 2238-2247

[40] LeibundGut-LandmannS, GrossO, RobinsonMJ, et al.. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol, 2007, 8(6): 630-638

[41] LibbyP. Inflammation in atherosclerosis. Nature, 2002, 420(6917): 868-874

[42] ClementM, BasatemurG, MastersL, et al.. Necrotic Cell Sensor Clec4e Promotes a Proatherogenic Macrophage Phenotype Through Activation of the Unfolded Protein Response. Circulation, 2016, 134(14): 1039-1051

[43] SalonenJT, Yla-HerttualaS, YamamotoR, et al.. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet, 1992, 339(8798): 883-887

[44] RhoadsJP, LukensJR, WilhelmAJ, et al.. Oxidized Low-Density Lipoprotein Immune Complex Priming of the Nlrp3 Inflammasome Involves TLR and FcgammaR Cooperation and Is Dependent on CARD9. J Immunol, 2017, 198(5): 2105-2114

[45] PetersonMR, HallerSE, RenJ, et al.. CARD9 as a potential target in cardiovascular disease. Drug Des Devel Ther, 2016, 10: 3799-3804

[46] ThiemK, HoekeG, van den BergS, et al.. Deletion of hematopoietic Dectin-2 or CARD9 does not protect against atherosclerotic plaque formation in hyperlipidemic mice. Sci Rep, 2019, 9(1): 4337-4347

[47] LassaleC, TzoulakiI, MoonsKGM, et al.. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J, 2018, 39(5): 397-406

[48] ChoiS, KimK, KimSM, et al.. Association of Obesity or Weight Change With Coronary Heart Disease Among Young Adults in South Korea. JAMA Intern Med, 2018, 178(8): 1060-1068

[49] WannametheeSG, ShaperAG, RumleyA, et al.. Lung function and risk of type 2 diabetes and fatal and nonfatal major coronary heart disease events: possible associations with inflammation. Diabetes Care, 2010, 33(9): 1990-1996

[50] HollidayMJ, FerraoR, de Leon BoenigG, et al.. Picomolar zinc binding modulates formation of Bcl10- nucleating assemblies of the caspase recruitment domain (CARD) of CARD9. J Biol Chem, 2018, 293(43): 16 803-16 817

[51] RenJ, YangM, QiG, et al.. Proinflammatory protein CARD9 is essential for infiltration of monocytic fibroblast precursors and cardiac fibrosis caused by Angiotensin II infusion. Am J Hypertens, 2011, 24(6): 701-707

[52] LiY, LiangP, JiangB, et al.. CARD9 inhibits mitochondria-dependent apoptosis of cardiomyocytes under oxidative stress via interacting with Apaf-1. Free Radic Biol Med, 2019, 141: 172-181

[53] LiuY, WangY, ShiH, et al.. CARD9 mediates necrotic smooth muscle cell-induced inflammation in macrophages contributing to neointima formation of vein grafts. Cardiovasc Res, 2015, 108(1): 148-158

[54] BourassaMG. Fate of venous grafts: the past, the present and the future. Journal of the J Am Coll Cardiol, 1991, 17(5): 1081-1083

[55] ShiHT, WangY, JiaLX, et al.. Cathepsin S contributes to macrophage migration via degradation of elastic fibre integrity to facilitate vein graft neointimal hyperplasia. Cardiovasc Res, 2014, 101(3): 454-463

[56] SterpettiAV, CucinaA, LepidiS, et al.. Formation of myointimal hyperplasia and cytokine production in experimental vein grafts. Surgery, 1998, 123(4): 461-469

[57] SterpettiAV, CucinaA, LepidiS, et al.. Formation of myointimal hyperplasia and cytokine production in experimental vein grafts. Surgery, 1998, 123(4): 461-469

[58] YangJ, ChaiL, GaoC, et al.. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood, 2008, 112(3): 805-813

[59] CanestraroM, GalimbertiS, SavliH, et al.. Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. Cancer Genet Cytogenet, 2010, 199(2): 110-120